However, late onset disease regression as evidenced by complete remission after the finalization of the vaccination treatment was recently observed in two patients with follicular lymphoma treated in a similar trial with a dual PD-L1/PD-L2-derived peptide vaccine (27). The gene discussed is CD274; the disease is follicular lymphoma.